Benzinga | Nov 15, 2021 10:53AM EST

Milestone Pharmaceuticals Announces Presentation Of Heart Rate Analysis Of NODE-301 Trial Of Etripamil In Patients With PSVT

- Etripamil significantly decreased heart rate during SVT episodes and independent of conversion to SR --

- HR changes occurred within 5 minutes and were sustained for 60 minutes --

- Data presented at AHA Scientific Sessions 2021 -